ArticleCell communication and signaling : CCS2025
Self-assembled nanoparticle vaccine comprised of multiple epitopes provides robust protective immunity against reoviruses in fish model.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Protective Efficacy of Vaccines Against Grass Carp Hemorrhagic Disease: A Systematic Review and Meta-Analysis.Journal of fish diseases · 2026Pooled it
- Comparative Genomics-Guided Epitope Prioritization and in Silico Design of a Multi-Epitope DNA Vaccine Candidate Against Megalocytivirus pagrus 1.Marine biotechnology (New York, N.Y.) · 2026Article
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Grass carp reovirus type II (GCRV-II) has inflicted substantial economic damage to aquaculture industry due to highly contagious. To combat epidemic GCRV-II, we rational designed and constructed a multi-epitope nanoparticle vaccine (Pep-Fn) that consisted with cell penetrating peptide (CPP), epitope peptides, cell and grass carp-derived ferritin. Firstly, an anti-GCRV-II phage antibody library was constructed to screen antibodies for outer capsid proteins VP4 and VP35. Ab-1 and Ab-3 were successfully screened and demonstrated high affinity with GCRV-II particles. We further identified five potential epitopes (Pep1-Pep5) on the outer capsid protein recognized by Ab-1 and Ab-3 through protein-protein docking and alanine scanning mutagenesis. Then, a self-assembled nanoparticle displaying the Pep1-Pep5 and CPP on the surface was constructed for Pep-Fn preparation. Benefit from the nano-sized particle structure, Pep-Fn could overcome the body surface barrier and accumulate in the immune organs. Experiments demonstrated that Pep-Fn could effectively stimulate grass carp to produce anti-GCRV-II antibodies via immersion immunization and also provided protective effect against GCRV-II challenge. Collectively, our research provides a new vaccine design strategy for combating GCRV-II, and demonstrates the great potential of protein-based nanoparticle as a platform for GCRV-II vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.